Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 161

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 161
---
. Consequently, we may encounter difficulties in protecting and defending such rights in foreign jurisdictions, and our competitors may use technologies in countries where we have not obtained patent protection. Additionally, trademark registration is required to enforce trademark rights in certain countries, and proceedings to enforce patent rights in foreign jurisdictions could be costly and time -consuming. Changes in the law and legal decisions by courts in foreign countries may also affect the ability to obtain adequate protection for technology and the enforcement of intellectual property. Companies must ultimately seek patent protection on a country -by -countrybasis, which is an expensive and uncertain process. In some countries, patents may provide limited or no benefit, and the legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. We may be unable to obtain sufficiently broad protection, or we may lose patent protection. As patent prosecution of biotechnology and pharmaceutical companies is highly uncertain, involves complex legal and factual questions, and has been the subject of litigation in recent years, the issuance, scope, validity, enforceability and commercial value of any future patent rights are highly uncertain. Our future patent applications may not result in granted patents that protect our drugs or technologies which would render us unable to prevent others from commercializing competitive drugs or technologies. The coverage of patent claims may be significantly reduced during patent prosecution before the patent is granted and the scope can also be reinterpreted after grant, which may not provide us meaningful protection, may not allow us to exclude competitors or may not provide us with any competitive advantage. We may not be able to protect and enforce our trademarks. Currently, we have a broad and diversified portfolio of trademarks, which represents a valuable asset for our company. Certain of our trademarks are registered in Mexico, Paraguay, Panama, Costa Rica, Argentina, Peru, Chile, Colombia, Panama and the Dominican Republic. However, this registry diversity may also pose challenges, particularly in terms of potential litigation, such as oppositions to applications for trademarks similar to ours. In addition, we have not yet registered certain of our trademarks in all of our potential markets. As we apply to register our unregistered 58 trademarks in the U.S. and other countries, our applications may not be allowed for registration in a timely fashion or at all, and our registered trademarks may not be maintained or enforced. For example, our application to register the “Rewell” trademark in Colombia was